FDA Approved: OXBRYTA — Original Application (Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.)

View source ↗

Summary

FDA approves OXBRYTA (voxelotor) for the treatment of sickle cell disease in adults and pediatric patients aged 12 months and older. This original application m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

ORIG AP for OXBRYTA (VOXELOTOR)